SmithKline Beckman Corp Boehringer Mannheim GmbH> sign final agreement develop market cardiovascular medicine discover Boehringer. Under agreement SmithKline responsibility develop product U.S. Both partner market product U.S. abroad. Initially SmithKline company concentrate clinical development marketing carvedilol compound treat mild moderate hypertension angina. An application marketing approval carvedilol submit West Germany December SmithKline said. Applications expect European market submission U.S. Food Drug Administration project 1990. It underway thromboxane receptor antagonist compound useful accelerate disolution blood clot prevent blod clot occur heart attack arterial diseases. The company compound clinical evaluation Europe U.S. Reuter 